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At-line static light scattering and fluorescence monitoring allows direct in-process
tracking of fluorescent virus-like particles. We have demonstrated this by coupling
at-line multi-angle light scattering and fluorescence detectors to the downstream pro-
cessing of enveloped virus-like particles. Since light scattering intensity is directly
proportional to particle concentration, our strategy allowed a swift identification
of product containing fractions and rapid process development. Virus-like particles
containing the Human Immunodeficiency Virus-1 Gag protein fused to the Green
Fluorescence protein were produced in Human Embryonic Kidney 293 cells by tran-
sient transfection. A single-column anion-exchange chromatography method was
used for direct capture and purification. The majority of host-cell protein impurities
passed through the column without binding. Virus-like particles bound to the column
were eluted by linear or step salt gradients. Particles recovered in the step gradient
purification were characterized by nanoparticle tracking analysis, size exclusion chro-
matography coupled to multi-angle light scattering and fluorescence detectors and
transmission electron microscopy. A total recovery of 66% for the fluorescent par-
ticles was obtained with a 50% yield in the main product peak. Virus-like parti-
cles were concentrated 17-fold to final a concentration of 4.45 × 1010 particles/mL.
Simple buffers and operation make this process suitable for large scale purposes.
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1 INTRODUCTION
The majority of the analytical techniques used in virus-like
particle (VLP) downstream processing (DSP) were imported
from protein DSP [1]. Typically, colorimetric methods such as
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Bradford assay and SDS-PAGE are used to gain insights into
the total protein content. In addition, assays such as Western
blot and ELISA allow the specific detection and quantifica-
tion of VLP specific proteins. However, none of these meth-
ods confirms the presence of correctly assembled VLPs, but
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only the presence of specific viral proteins, which, when in
their free state, represent one of the product related impurities.
Particle morphology is usually confirmed by high-resolution
microscopy techniques such as TEM and multi-frequency
atomic force microscopy [2]. Particle number and size dis-
tributions are frequently measured by nanoparticle tracking
analysis (NTA) and dynamic or static light scattering [3–
5]. However, these methods are non-specific regarding the
particle’s composition and consider all structures with the
same hydrodynamic or geometric radius as equals. As a result,
a combination of biochemical, biophysical, and biological
analytical methods is required to ensure an accurate detec-
tion and quantification of VLPs. This results in very laborious
and time-consuming process analytics and hinders DSP pro-
cess development, which is strongly dependent on the ability
to detect, quantify and characterize the product of interest as
well as on the capacity to discriminate the product from its
related impurities.
Multi-angle light scattering (MALS) is one of the most
used techniques for quantification and characterization of dif-
ferent nanoparticles [6]. Usually, monodisperse samples are
required to allow for structural characterization based on light
scattering. Typically, SEC or asymmetric flow field-flow frac-
tionation are used to first separate the samples before the mea-
surement [4,7]. Nevertheless, the intensity of scattered light
by particles in solution is directly proportional to the parti-
cle concentration [8,9]. Thus, an at-line MALS detector can
be used for fast detection and semi-quantification of particles
without the requirement of monodisperse samples. This rapid
method could be used as an in-process control to speed up
process development and optimization.
Outbreaks of Flu, Ebola, and Zika in the last decade
reinforced the need for faster process development and
flexible manufacturing platforms which enable the produc-
tion of millions of vaccine doses in a short time [10,11].
Among different candidates, retroviral-based VLPs are
promising towards the development of vaccines and drug
delivery systems [12,13]. Enveloped virus-like particles
(eVLPs) are produced by recombinantly expressing one or
more viral proteins [10–12]. As a model, we used eVLPs
produced in Human Embryonic Kidney (HEK) 293 cells
by recombinantly expressing the Human Immunodeficiency
Virus-1 (HIV-1) group specific antigen (Gag) protein which
was fused to Green Fluorescence protein (GFP) [2,14–16].
Similar to the native HIV-1 production process, upon
recombinant expression, Gag polyprotein self-assembles
underneath the cell membrane and VLPs bud to the extracel-
lular space as spherical particles [17]. The resulting particles
are enveloped by a host-cell derived lipid bilayer and have
a diameter of 100–200 nm [4,18,19]. The integration of
GFP permits the use of fluorescence-based techniques as an
orthogonal method for detection and quantification of HIV-1
Gag-GFP VLPs.
Different DSP strategies have been developed for the purifi-
cation of bionanoparticles [5,11,20–22]. Monolithic columns
have been often used for the direct capture and purification of
enveloped virus and VLPs from cell culture supernatant [23–
27]. Due to its convective pore structure, high binding capaci-
ties can be achieved in monolithic columns while maintaining
high flow rates. This results in higher productivities when
compared with traditional VLP purification methods such as
density gradient centrifugation [28]. As a model purification
strategy, we used anion exchange monolithic columns for
the direct capture and purification of HIV-1 Gag-GFP VLPs
directly from cell culture supernatant. We show how at-line
MALS and fluorescence detectors simplified DSP process
development and optimization. Furthermore, size exclusion
chromatography coupled to multi-angle light scattering and
fluorescence (SEC-MALS-FL) is an effective method for
particle quantification and characterization.
2 MATERIALS AND METHODS
2.1 Chemicals
The chemicals used for all experiments were acquired from
Merck (Darmstadt, Germany) or Sigma Aldrich (St. Louis,
MO, USA).
2.2 Production of virus-like particles
2.2.1 Cell line, media, and culture conditions
A serum-free suspension-adapted Human Embryonic Kid-
ney 293 cells (HEK 293) cell line (HEK293SF-3F6, National
Research Council, Montreal, Canada) kindly provided by Dr.
Amine Kamen from McGill University (McGill, Montreal,
Canada) was used. Cells were cultured in Freestyle 293®
medium supplemented with 0.1% Pluronic® (both Invitrogen,
Carlsbad, CA, USA), 1.6 mg/L of r-transferrin (Merck Mil-
lipore, Kankakee, IL, USA), 19.8 mg/L of r-insulin (Novo
Nordisk Pharmatek, Køge, Denmark), and 0.9X of an in-
house developed lipid mixture to maximize cell growth [8].
Cells were routinely maintained in 20 mL of culture medium.
Flasks were shaken at 130 rpm using an orbital shaker (Stu-
art, Stone, UK) placed in an incubator maintained at 37˚C in
a humidified atmosphere of 5% CO2 in air.
2.2.2 Plasmids
The pGag-eGFP plasmid used in this work codes for a
Rev-independent HIV-1 Gag protein fused in frame to
the enhanced GFP [27]. The plasmid from the NIH AIDS
Reagent Program (Cat 11468) was constructed by cloning the
Gag sequence from pCMV55M1-10 [28] into the pEGFP-N1
plasmid (Clontech, Takara Bio, Mountain View, CA, USA).
The plasmids were prepared and purified as previously
described with Endofree Plasmid Mega kit (Qiagen, Hilden,
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Germany) [29]. Snap Gene Viewer was used to analyse the
plasmid features (GSL Biotech, Chicago, IL, USA).
2.2.3 DNA/polyethilenimine complex
formation and transient transfection of HEK
293 cells
HEK 293 suspension cells were transiently transfected
using 25 kDa linear polyethilenimine (PEI) (PolySciences,
Warrington, FO, USA). Transfections were performed using
a final DNA concentration of 1 μg/mL. PEI/DNA com-
plexes were formed by adding PEI to plasmid DNA (1:2 w/w
DNA:PEI ratio) diluted in fresh culture medium (10% of the
total culture volume to be transfected) [8].
Cells were cultured for 72 h post transfection to maximize
VLP yields [30]. Cell culture supernatants were primary har-
vested by centrifugation at 4000 g for 30 min at 4˚C. Recov-
ered supernatants were stored at 4˚C before purification.
2.3 Chromatographic purification
2.3.1 Chromatographic equipment and
mobile phases
Chromatographic experiments were performed using an Äkta
pure 25 M2 with a sample pump S9 and fraction collector F9-
C (GE Healthcare, Uppsala, Sweden). During the purification
runs, pH, conductivity and UV absorbance at 280 and 260 nm
wavelengths were monitored. Unicorn software versions 5.10
or 6.4.1 (GE Healthcare, Uppsala, Sweden) were used for
method programming, system control, and data acquisition.
Mobile phase A and B consisted in 50 mM HEPES, pH 7.2
and 50 mM HEPES, 2 M NaCl, pH 7.2 respectively. Sanitiza-
tion buffer consisted in 1 M NaOH.
2.3.2 Preparative scale purification
Clarified cell culture supernatant containing HIV-1 Gag-GFP
VLPs was 0.8 μm filtered (Millex AA syringe filter, Millipore
Bedford, MA, USA) and 100 mL were loaded into a 1 mL
radial flow monolith (CIMmultusTM QA, BIA Separations,
Ajdovščina, Slovenia). Before loading, the column was equili-
brated with 50 mM HEPES, 100 mM NaCl, pH 7.2 (5% buffer
B). After the loading phase, the column was washed with equi-
libration buffer (5% buffer B) for 15 column volumes (CV).
In the linear gradient purification, a salt linear gradient from
100 to 1000 mM NaCl (5 to 50% buffer B) in 50 CV was used.
For the step gradient purification, three steps of 300, 520 and
1000 mM NaCl (15, 26 and 50% buffer B) with 15 CV each
were used for elution. In both purification strategies, the col-
umn was regenerated with 100% buffer B in a 10 CV step.
After regeneration, the column was sanitized using 10 CV of
1 M NaOH. All preparative purification runs were performed
using a flow rate of 1 mL/min. The sample was loaded into
the column using the sample pump. Fractions of 1 mL were
collected in 96 deep-well plates and pooled according to the
chromatograms.
2.4 Nanoparticle tracking analysis
Particle concentration and particle size distribution were
determined by NTA using a NanoSight NS300 (Malvern
Instruments, Worcestershire, UK) equipped with a blue laser
module (488 nm), a neutral density filter and a 500 nm
fluorescence filter. To obtain a particle concentration of 20 to
80 particles per video frame in the measuring chamber, sam-
ples were serially diluted using particle-free water or 0.1 μm
filtered 50 mM HEPES pH 7.2 buffer. Each sample was mea-
sured with both scattering (LS) and fluorescence (FL) modes
in three different dilutions in triplicates. In total, nine videos
of 60 s were recorded per sample. The camera level varied
between 14 and 16 and it was manually adjusted prior to
each measurement. Recorded videos were analysed using the
NanoSight NTA software version 3.2 (Malvern Instruments,
Worcestershire, UK). Detection thresholds between 3 and
5 were used.
2.5 Total protein and double stranded DNA
quantification
Total protein concentration was determined by Bradford assay
using Coomassie blue G-250-based protein dye reagent (Bio-
Rad Laboratories, Hercules, CA, USA). The calibration curve
was obtained using BSA standards (Thermo Fisher Scien-
tific, Waltham, MA, USA) diluted in TE-Buffer to a con-
centration range of 50–200 μg/mL. Double stranded DNA
(dsDNA) quantification was performed using the Quant-
iTTM PicoGreen® dsDNA kit (Life Technologies, Waltham,
MA, USA). Protein and dsDNA assays were performed
according to the respective instructions from the manufac-
turer in a 96-well plate format. Since HIV-1 Gag-GFP VLPs
emit at the same range as the Quant-iTTM PicoGreen®
reagent, the native fluorescence was measured prior to the
reagent addition and later subtracted to the fluorescence after
the reaction.
2.6 Sodium dodecyl sulfate-polyacrylamide
gel electrophoresis and Western blot analysis
Precast NuPAGE Bis/Tris gels 4–12% (Invitrogen, Carlsbad,
CA, USA) were used in a MES-SDS buffer system. The pro-
tocol was adapted from manufacturer’s instructions. Briefly:
40 μL of sample were mixed with 20 μL of 4x LDS buffer
and 2 M DTT to a final concentration of 1% v/v. Each sam-
ple incubated at 95◦C for 20 min. SeeBlue® Plus2 Pre-stained
Protein Standard (Invitrogen, Carlsbad, CA, USA) was used
as protein marker. Gels were run at 200 V, 400 mA. Coomassie
Brilliant Blue G-250 based EZBlueTM Gel Staining Reagent
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(Sigma Aldrich, St. Louis, MO, USA) was used for protein
staining. After SDS-PAGE, proteins were blotted using Trans-
Blot® turbo system (Bio-Rad Laboratories, Hercules, CA,
USA) with 0.2 μm nitrocellulose membranes and blocked with
3% BSA in PBS with 0.1% w/v Tween-20 overnight. Detec-
tion of HIV-1 Gag-GFP protein was performed by incuba-
tion with primary mouse monoclonal antibody against HIV-
1 p24 (Icosagen AS, Tartumaa, Estonia), diluted 1:1000 in
PBS-T containing 1% BSA for 2 h. Anti-mouse IgG conju-
gated with alkaline phosphatase (Sigma Aldrich, St. Louis,
MO, USA), diluted 1:1000 in PBS-T with 1% w/v BSA was
used as secondary antibody. Premixed BCIP®/NBT solution
(Sigma Aldrich, St. Louis, MO, USA) was used as substrate
solution.
2.7 At-line multi-angle light scattering and
fluorescence
At-line MALS and fluorescence measurements were per-
formed using an Ultimate 3000 system (Thermo Fisher,
Waltham, MA, USA). A sample of all collected fractions dur-
ing the purification runs was directly injected into the detec-
tors bypassing the column. The HPLC system was equipped
with a LPG-3400SD quaternary pump, WPS-3000TSL ana-
lytical autosampler, DAD 3000 UV-detector and FLD 3100
fluorescence detector (Thermo Fisher, Waltham, MA, USA).
Additionally, the system was connected to a multi-angle light
scattering detector DAWN HELEOS 18-angle and a differen-
tial refractive index detector Optilab rEX (both Wyatt, Santa
Barbara, CA, USA). Chromeleon 7 (Thermo Fisher Scien-
tific, Waltham, MA, USA) and Astra 5.3.4 Wyatt, (Santa Bar-
bara, CA, USA) software were used for method program-
ming, system control and data acquisition. GFP fluorescence
was monitored with an excitation wavelength of 480 nm
and emission of 505 nm. Analysis time was 3 min/sample.
Light scattering intensity was accessed by calculating the
peak area of the light scattering signal obtained with the
90◦ angle.
2.8 Size exclusion chromatography coupled to
multi-angle light scattering and fluorescence
SEC-MALS-FL measurements were performed using the
same HPLC system, detectors and software as described in
Section 2.7.
A TSKgel G5000PWXL 300.0 mm × 7.8 mm i.d. in com-
bination with a TSKgel PWXL guard column 40.0 mm ×
6.0 mm i.d. (both Tosoh Bioscience, Stuttgart, Germany) were
used for size exclusion chromatography. The method was
previously described by Steppert et al. [20]. Data analysis
was done in Astra 6.1.2 using the number density procedure
and the sphere model fit with a particle refractive index of
1.46 [29].
2.9 TEM
HIV-1 Gag-GFP VLP samples were prepared by air-dried
negative staining method. Briefly, 8 μL of sample was placed
on discharged carbon-coated copper or holly carbon 200 mesh
grids and incubated at room temperature for 1 min. Excess
sample was drained carefully off the grid with filter paper.
Samples were stained negatively with 8 μL of uranyl acetate
(2%) by incubation for 1 min at room temperature. Excess
stain was drained off as before, and grids were dried. Micro-
graphs were taken with a JEM-400 transmission electron
microscope (JEOL USA, Pleasanton, CA, USA) equipped
with an ES1000W Erlangshen charge-coupled device camera
(Model No. 785; Gatan, Pleasanton, CA, USA).
3 RESULTS AND DISCUSSION
In this work, we aimed to streamline the process development
for enveloped virus-like particle purification by including at-
line multi-angle light scattering and fluorescence detectors for
high-throughput particle detection and semi-quantification.
Since it has been shown that strong anion-exchange monoliths
allow the simultaneous capture and purification of enveloped
bionanoparticles such as eVLPs and exosomes [22,23], we
used a QA monolith to capture and purify HIV-1 Gag-GFP
VLPs directly from HEK 293 cell culture supernatant in a
single step. As a starting point, a salt linear gradient was
used for VLP elution. Later, the data obtained in the at-line
MALS and fluorescence measurements were used to develop
a salt step elution strategy, providing a base for potential
scale-up.
3.1 Linear gradient purification
HIV-1 Gag-GFP VLPs were produced by transient transfec-
tion in HEK 293 cells. For VLP capture and purification in a
single step, 100 mL of clarified and filtered cell culture super-
natant were loaded into a 1 mL QA monolith. Elution was
achieved by a 50 CV salt linear gradient from 100 to 1000 mM
NaCl. Fractions of 1 mL were collected in 96 deep-well plates
and directly injected into the at-line MALS and fluorescence
detectors. For each elution fraction, the total light scattering
intensity and the total fluorescence were calculated by inte-
grating the signals measured by the MALS and fluorescence
detectors, respectively. Data were plotted together with the
purification run chromatogram (Figure 1). Since light scat-
tering intensity is directly proportional to particle concentra-
tion [8] and the main structural element of the VLPs (Gag-
GFP protein) is fluorescent [30], this method allows a fast
detection and semi-quantification of HIV-1 Gag-GFP VLPs
and subsequently a fast identification of the fractions contain-
ing the product of interest is possible. Considering the total
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F I G U R E 1 Chromatogram of the linear gradient purification of HIV-1 Gag-GFP VLP using a QA monolith. The loading material was
100 mL of clarified and 0.8 μm filtered HEK 293 cell culture supernatant. Bars represent the area under the curve of the light scattering intensity
(grey) and fluorescence (green) at-line measurements. FT: flow-through; W: wash; P1-P5: polled fractions for peaks 1–5
T A B L E 1 Total protein and dsDNA mass balance of the purification of HIV-1 Gag-GFP VLPs using a linear gradient elution (Figure 1).










S 100 310.9 – 1387.5 –
L 100 313.1 100.0 1289.4 100.0
FT 100 134.9 43.1 37.5 2.9
W 15 <LLOQ – <LLOQ –
P1 7 367.6 8.2 10.2 0.1
P2 5 275.1 4.4 310.5 1.2
P3 6 <LLOQ – 5114.5 23.8
P4 6 <LLOQ – 3129.6 14.6
P5 2 <LLOQ – 1108.3 1.7
Recovery 55.7 44.3
<LLOQ: lower than the lower LOQ
light scattering intensity and the total fluorescence data, the
majority of VLPs eluted from approximately 130 to 142 mL,
corresponding to a conductivity range of 27–49 mS/cm. It is
important to note that neither UV 280 nor UV 260 signals pro-
vide a good representation of the VLPs elution profile. This
fact is one of the challenges in bionanoparticles process devel-
opment, especially in early stage development where titers are
usually low.
In order to determine the total protein and dsDNA com-
position of the fractions, samples were pooled according
to the chromatogram (Figure 1) and analysed by Bradford
and Picogreen assays respectively (Table 1). Due to the
relatively high conductivity of the cell culture supernatant
(11.8 mS/cm), 43% of the protein impurities did not bind
to the column and were collected during column loading in
the flow-through fraction (FT). Additionally, weakly bound
proteins eluted immediately at the beginning of the salt linear
gradient (fraction P1). Comparable results were obtained
when using conditioned media harvested prior to transfection
as loading material (data not shown). Contrariwise, the
majority of the dsDNA bound to the column and only
3% was recovered in the FT fraction. Elution of dsDNA
was achieved at conductivities higher than 50 mS/cm and
collected in the fractions P3 and P4, in which the total
protein content was very low (Table 1 and Figure 2A).
Western blot analysis detecting HIV-1 p24 confirmed the
presence of the Gag-GFP protein in all elution fractions (band
at approximately 88 kDa, Figure 2B, P1-P5). Little or no
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F I G U R E 2 (A) SDS-PAGE and (B) Western blot analysis of the pooled fractions from the linear gradient purification (Figure 1). M:
molecular weight marker; S: cell culture supernatant; L: loading material; FT: flow-through; W: wash; P1-P5: pooled fractions for peaks 1–5
F I G U R E 3 Chromatogram of the step
gradient purification of HIV-1 Gag-GFP VLP
using a QA monolith. The loading material was
100 mL of clarified and 0.8 μm filtered HEK 293
cell culture supernatant. FT: flow-through; W:
wash; P1-P4: pooled fractions for peaks 1–4
signal was obtained for the fractions FT and W in the Western
blot, confirming the successful binding of the VLPs to the
column. According to the light scattering and fluorescence
data, the fraction P2 contains the majority of the HIV-1
Gag-GFP VLPs. Comparing the total protein and dsDNA
content of P2 with the loading material (L), a depletion
of approximately 96% of total protein and 99% of dsDNA
was achieved. In P3 and P4, VLPs and host cell dsDNA
co-eluted. Enveloped VLPs and dsDNA co-elution during
purification using anion-exchange chromatography has been
previously reported [23].
The at-line MALS and fluorescence monitoring allowed a
fast identification of the VLP containing fractions and a direct
transfer from the linear gradient to a step gradient elution. In
the next chapter, we describe the step gradient purification.
3.2 Step gradient purification
The step gradient purification was designed based on the
results obtained by the at-line MALS and fluorescence
monitoring of the linear gradient purification. The same col-
umn and loading material were used. Column equilibration,
loading and regeneration conditions were also kept constant.
Elution was designed targeting the recovery of the VLPs
eluted in the linear gradient purification in a conductivity
range of 27–49 mS/cm, as well as targeting the separation
of VLPs from weakly bound protein impurities and from
strongly bound dsDNA. Therefore, elution consisted in three
steps of 15 CV each, using 300, 520, and 1000 mM NaCl
(15, 26 and 50% B), corresponding to approximately 30,
49, and 86 mS/cm. In order to characterize the fractions
collected in each step, samples were pooled according to
the chromatogram (Figure 3). Protein content was analyzed
by SDS-PAGE and Western blot and total protein was
quantified by Bradford analysis (Figures 4A and B, Table 2).
Picogreen assay was used to determine the dsDNA content
(Table 2). Particles were visualized by transmission electron
microscopy (Figures 4C–E) and quantified by NTA in
scattering and fluorescence modes (Table 2).
As in the linear gradient purification, most of the protein
impurities (55%) did not bind to the column or were eluted
in fraction P1 using 300 mM NaCl (30 mS/cm). Western
blot analysis confirmed the presence of Gag-GFP protein in
fraction P1, however only a small number of particles were
recovered in this fraction (3–5% measures by NTA in scat-
tering or fluorescence mode). This indicates the presence of
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F I G U R E 4 A: SDS-PAGE and B: Western blot analysis of the pooled fractions from the step gradient purification (Figure 3). (C), (D), and (E)
electron microscopy micrographs of loading material (L) and fractions P2 and P3, respectively. M: molecular weight marker; S: cell culture
supernatant; L: loading material; FT: flow-through; W: wash; P1-P4: pooled fractions for peaks 1–4
T A B L E 2 Particles (diameter: 100–200 nm), total protein and dsDNA mass balance of the purification of HIV-1 Gag-GFP VLPs using a step























L 100 2.4 × 1010 100.0 2.7 × 1009 100.0 297.8 100.0 448.0 100.0
FT 100 <LLOQ – <LLOQ – 126.7 42.5 39.2 8.8
W 15 <LLOQ – <LLOQ – 41.0 2.1 645.5 21.6
P1 5 2.2 × 1010 4.5 1.5 × 1009 2.8 632.2 10.6 91.5 1.0
P2 3 1.3 × 1011 16.5 4.5 × 1010 49.9 510.3 5.1 975.4 6.5
P3 3 2.7 × 1010 3.3 1.2 × 1010 13.6 62.4 0.6 12747.8 85.4
P4 1 5.0 × 1009 0.2 <LLOQ – <LLOQ – 691.6 1.5
CIP 15 n.d. – n.d. – 456.8 23.0 <LLOQ –
Recovery 24.5 66.3 83.9 124.8
aParticles measured in light scattering (LS) mode
bParticles measured in fluorescence (FL) mode
<LLOQ: lower than the lower LOQ
n.d.: not determined
fragmented particles or free Gag-GFP protein, which did not
form a correctly assembled VLP. No particles were found in
the flow-through (FT) and wash (W) fractions, confirming
the efficient capture of the VLPs by the monolithic column.
As expected, most particles were recovered and concentrated
in fraction P2 (17–50%) and Western blot analysis confirmed
the presence of the Gag-GFP protein. TEM micrographs con-
firmed the presence of correctly assembled spherical parti-
cles. Comparing the total protein and dsDNA content of P2
with the loading material (L), a depletion of approximately
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F I G U R E 5 Analysis of the fractions P1-P4 from the step gradient purification (Figure 3) by analytical size exclusion chromatography coupled
to MALS and fluorescence detectors (SEC-MALS-FL). (A) P1; (B) P2; (C) P3; (D) P4
95% of total protein and 94% of dsDNA was achieved for
the main product fraction during the step gradient purifica-
tion. Lastly, as in the linear gradient purification, the major-
ity of dsDNA (85%) was eluted using higher ionic strength
(1000 mM NaCl) and collected in fraction P3 together with
strongly bound particles (3–14%).
In order to further characterize the samples, size exclusion
chromatography coupled to MALS and fluorescence detec-
tors (SEC-MALS-FL) was used. This strategy allows the sep-
aration of correctly assembled HIV-1 Gag-GFP VLPs from
free Gag-GFP proteins and/or protein aggregates smaller than
100 nm, which are still identified when using Western blot
analysis as detection method. As VLP reference, HIV-1 gag
VLPs produced in CHO cells and purified as described by
Steppert et al [23] were used. As free protein reference, GFP
standard was used. VLPs standard eluted in the void vol-
ume of the SEC column (approximately 20 min) while GFP
standard elutes at approximately 35 min post injection (data
not shown). Fractions P1, P2, P3, and P4 were analysed by
SEC-MALS-FL (Figures 5A–D respectively). As expected,
in fraction P1 (Figure 5A) a very small light scattering peak
was measured at the void volume due to the very low num-
ber of particles in this fraction. On the other hand, a signifi-
cant fluorescence signal was obtained at 35 min, confirming
the presence of free Gag-GFP protein already indicated by the
Western blot analysis (Figure 3B). Conversely, in fraction P2
(Figure 5B) a significant light scattering signal together with
a significant fluorescence signal were observed at the void
volume confirming the presence of correctly assembled HIV-
1 Gag-GFP VLPs. The small fluorescence peak observed at
35 min indicates that the sample still contains a small amount
of product related impurities (free Gag-GFP). Similarly to
fraction P2, fraction P3 SEC-MALS-FL analysis (Figure 5C)
indicates the presence of correctly assembled particles, how-
ever in lower concentration due to the lower light scattering
signal intensity. This could also be observed in the measure-
ments done by NTA (Table 2).
MALS data was also used to calculate the geometric radius
of particles in fractions P2 and P3, using the Rayleigh-Gans-
Debye approximation. Geometric radii of approximately
70 nm (140 nm of diameter) and 69 nm (138 nm of diameter)
were obtained for fractions P2 and P3, respectively. These
values are in agreement with the values obtained for the
hydrodynamic radii of 126 and 140 nm for fractions P2
and P3, respectively, calculated using the Stokes-Einstein
equation and the diffusion constant measured by NTA.
SEC-MALS-FL validated at-line MALS results as a robust
analytical tool to DSP development. Furthermore, VLP
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integrity was confirmed by traditional TEM micrographs,
where VLPs were clearly distinguished from product-related
impurities.
4 CONCLUDING REMARKS
The use of at-line multi-angle light scattering and fluores-
cence monitoring of a purification strategy for fluorescent
VLPs allowed not only in-process monitoring and control but
also faster process development. Product-containing fractions
were quickly identified, allowing a swift transition from a lin-
ear gradient to a step gradient elution, providing a base for
potential scale-up.
The single-step purification using a QA-monolith effec-
tively captured and purified HIV-1 Gag-GFP VLPs produced
in HEK 293 cells directly from the clarified cell culture
supernatant. A VLP yield of 50% (measured by NTA in flu-
orescence mode) was obtained with a 17-fold concentration
factor regarding the loading material. Assuming a dose of 109
particles, more than 44 doses can be captured per mL column.
This strategy streamlines VLP DSP process development
and optimization and minimizes the need for several time-
consuming and laborious analytical techniques during severe
viral outbreaks.
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